Whalesbook
📉 The Financial Deep Dive
The Numbers:
Neuland Laboratories reported a 10.47% year-on-year (YoY) increase in consolidated revenue from operations for the third quarter of fiscal year 2026 (Q3 FY26) to ₹43,970.93 lakhs, up from ₹39,803.18 lakhs in Q3 FY25. Sequentially, however, revenue declined by 14.50% from ₹51,427.31 lakhs in Q2 FY26.
Profitability witnessed a significant downturn. Consolidated Profit After Tax (PAT) for Q3 FY26 plummeted by 60.06% YoY to ₹4,057.19 lakhs, down from ₹10,158.68 lakhs in the prior year period. Earnings Per Share (EPS) mirrored this trend, dropping from ₹79.18 to ₹31.62 YoY.
For the nine-month period ended December 31, 2025 (9M FY26), consolidated revenue grew 8.55% YoY to ₹1,24,673.51 lakhs. However, consolidated PAT decreased substantially by 34.92% YoY to ₹15,132.58 lakhs.
The Quality:
Analysis of the income statement reveals that while revenue grew, expenses surged. The cost of materials consumed increased by a substantial 37.47% YoY for the quarter and 72.73% for the nine months. Other expenses also saw notable increases, contributing to a severe compression in operating margins. Consolidated Profit Before Tax (PBT) for Q3 FY26 was ₹5,447.54 lakhs, a 57.37% decline YoY, with the PBT margin compressing drastically from 32.10% in Q3 FY25 to 12.39% in Q3 FY26.
An ambiguity exists in the reporting of exceptional items. While Note 5 mentions an exceptional profit from investment property transfer, the reported PBT figures suggest different impacts for Q3 FY26 and Q3 FY25, requiring further clarification from the management.
The Grill:
Analysts will likely question management intensely on the drivers behind the sharp increase in the cost of materials and other expenses, which have disproportionately impacted profitability despite revenue growth. The severe margin compression, from over 32% to under 13% on a PBT basis, is a major concern. Furthermore, the decline in revenue from India (-34.34% YoY) and Rest of the World (-33.81% YoY), contrasting with growth in USA (+49.16% YoY) and Europe (+14.94% YoY), warrants explanation. The lack of forward-looking guidance and the ambiguity in exceptional item reporting are key points that will be raised.
Risks & Outlook:
Key risks include persistent inflation in input costs, potential inability to pass on costs to customers, execution challenges in expanding revenue in growth geographies while stemming declines elsewhere, and the need for clarity on the accounting for exceptional items. Investors will watch for management's strategy to improve margins, control costs, and provide clear guidance for the upcoming quarters. The absence of balance sheet and cash flow details in this announcement also limits a comprehensive short-term assessment.